News

An analysis into correlation between COVID-19 vaccine uptake and that of more established vaccines showed research is lacking—yet troubling all the same.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.

This new analysis demonstrated the importance of carefully considering the unintended results of removing race correction from PFTs to prevent exacerbating disparities among Black patients.

In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.

Early rapid weight gain after diagnosis of T1D may play a role in the lack of remission and shorter duration of partial remission, potentially due to altered insulin sensitivity.

The adjusted odds of vision testing decreased by 41% for uninsured and 24% for publicly insured participants versus those with private insurance.

In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.

Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.

This new data indicated a necessity for clinical strategies made to handle unintentional pathogenic or likely pathogenic germline variants seen in tumor-only next-generation sequencing.

Trends show e-cigarette use in patients with CVD decreased from 2015 to 2019, but rebounded in 2019, potentially owing to the COVID-19 pandemic.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

This new research letter highlights several trends in prescribing by both dermatologists and non-dermatologists from 2017 to 2020.

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.

The FDA approval of pozelimab (Veopoz) makes it the first and only treatment indicated for children and adults with CHAPLE disease.

The study met its primary endpoint of PASI improvement in the biosimilar and bio-originator cohorts.

This new research indicates that while there are ongoing trials seeking to define which individuals with subsegmental PE may be surveilled, greater uptake of newer surveillance actions may necessitate more than passive diffusion.

CKD-aP patients receiving maintenance hemodialysis reported adverse clinical events in line with their pruritus severity and were found to be at greater risk of all-cause mortality, all-cause hospitalization, and cardiovascular events.

In this Q&A interview with Dr. Rieder, he describes the biggest takeaways from his panel discussion on the mental health needs of dermatology patients.

Enhancing access to biosimilars in the US involves multiple key factors, including active participation from payers, providers, and the healthcare community to incentivize the utilization of biosimilars.

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.

In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 presentations from ASRS 2023. The discussion centered around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.

The FDA has updated its list of UV wands, used to disinfect surfaces, to avoid due to potentially harmful levels of radiation exposure.

Several key initiatives designed to streamline and enhance the efficiency of biosimilar development in the US market are underway, underscoring the timeliness of the Biosimilars Forum's recent report.

This segment of Dr. Eichenfield’s interview featured a discussion about Eichenfield’s response to the FDA’s approval of cantharadin 0.7%, or VP-102, for molluscum contagiosum.

A new study revealed differences in the diagnostic performance of the FIB-4 and NFS, indicating that conventional NFS cutoff values may be unsuitable for screening lean NAFLD patients.

In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th anniversary celebration.

In his latest recorded interview, Dr. Eichenfield described the use of VP-102, or cantharidin 0.7%, for molluscum contagiosum.